Annals of Oncology Advance Access published online on December 13, 2007
Annals of Oncology, doi:10.1093/annonc/mdm502
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2007 European Society for Medical Oncology
Randomized phase II study of irinotecan, leucovorin and 5-fluorouracil (ILF) versus cisplatin plus ILF (PILF) combination chemotherapy for advanced gastric cancer
1 Division of Hematology and Oncology, Department of Internal Medicine
2 Department of General Surgery, Gachon University Gil Medical Center, Incheon
3 Department of Internal Medicine, Dankook University Hospital, Cheonan, Korea
* Correspondence to: Dr D. B. Shin, Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon 405-760, Korea. Tel: +82-32-460-3817; Fax: +82-32-460-3233; E-mail: dbs{at}gilhospital.com
Background: Irinotecan, in combination with 5-fluorouracil (5-FU) or cisplatin, has demonstrated efficacy against advanced gastric cancer (AGC).
Patients and methods: Chemotherapy-naive AGC patients were randomly assigned to receive irinotecan 150 mg/m2 on day 1, leucovorin 20 mg/m2 and a 22-h infusion of 5-FU 1000 mg/m2 on days 1 and 2 (ILF) or ILF plus cisplatin 30 mg/m2 on day 2 (PILF). Treatment was repeated every 2 weeks.
Results: Of 91 registered patients, 45 patients were treated with ILF and 45 with PILF. For both arms, 687 chemotherapy cycles were delivered (median = 7 for ILF and 8 for PILF). Both ILF and PILF were generally well tolerated and there was no relevant difference in the occurrence of overall grade 3/4 toxic effects between the two arms. Four patients died during treatment: one in the ILF and three in the PILF arm. The objective response rate was 42% for both arms. There was no significant difference in therapeutic efficacy between ILF and PILF with respect to progression-free survival (4.8 versus 6.2 months; P = 0.523) and overall survival (10.7 versus 10.5 months; P = 0.850).
Conclusion: Both ILF and PILF are active as first-line chemotherapy for AGC. The addition of cisplatin, however, has no clear advantage over ILF.
chemotherapy, cisplatin, 5-fluorouracil, irinotecan, stomach cancer
Received for publication July 16, 2007. Revision received September 27, 2007. Accepted for publication September 28, 2007.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Moehler, S. Kanzler, M. Geissler, J. Raedle, M. P. Ebert, S. Daum, D. Flieger, T. Seufferlein, P. R. Galle, T. Hoehler, et al. A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction Ann. Onc., July 15, 2009; (2009) mdp269v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-D. Seo, K.-W. Lee, J. H. Lim, H. G. Yi, D.-Y. Kim, D.-Y. Oh, J. H. Kim, S.-A. Im, T.-Y. Kim, J. S. Lee, et al. Irinotecan Combined with 5-Fluorouracil and Leucovorin as Second-line Chemotherapy for Metastatic or Relapsed Gastric Cancer Jpn. J. Clin. Oncol., September 1, 2008; 38(9): 589 - 595. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. I. Khushalani Cancer of the Esophagus and Stomach Mayo Clin. Proc., June 1, 2008; 83(6): 712 - 722. [Abstract] [Full Text] [PDF]
|
|